Annexon Beheer
Beheer criteriumcontroles 4/4
De CEO Annexon is Doug Love, benoemd in Dec2014, heeft een ambtstermijn van 9.92 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 2.45M, bestaande uit 24.2% salaris en 75.8% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.28% van de aandelen van het bedrijf, ter waarde $ 2.16M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.5 jaar en 6.1 jaar.
Belangrijke informatie
Doug Love
Algemeen directeur
US$2.5m
Totale compensatie
| Percentage CEO-salaris | 24.2% |
| Dienstverband CEO | 9.9yrs |
| Eigendom CEO | 0.3% |
| Management gemiddelde ambtstermijn | 2.5yrs |
| Gemiddelde ambtstermijn bestuur | 6.1yrs |
Recente managementupdates
Recent updates
We're Hopeful That Annexon (NASDAQ:ANNX) Will Use Its Cash Wisely
Sep 27
Speculative "Buy" Rating On Annexon: Evaluating The Potential Of ANX005 For GBS
Aug 17Annexon: Complement Inhibition Of GBS Only The Beginning With Strong Tech In Place
Jun 04Annexon: Unforced Error Sullies Prospects
Apr 03Here's Why We're Watching Annexon's (NASDAQ:ANNX) Cash Burn Situation
Nov 10Is Annexon (NASDAQ:ANNX) In A Good Position To Deliver On Growth Plans?
Jul 25Is Annexon (NASDAQ:ANNX) In A Good Position To Deliver On Growth Plans?
Apr 11Are Investors Undervaluing Annexon, Inc. (NASDAQ:ANNX) By 25%?
Feb 14We Think Annexon (NASDAQ:ANNX) Needs To Drive Business Growth Carefully
Dec 28Annexon started as a buy at Jefferies on market potential of candidates, data catalysts
Sep 16Annexon: A First Take
Aug 21Annexon Biosciences GAAP EPS of -$0.96 misses by $0.02
Aug 08Annexon to raise $130M in stock and warrant offering
Jul 08We're Keeping An Eye On Annexon's (NASDAQ:ANNX) Cash Burn Rate
Apr 16Companies Like Annexon (NASDAQ:ANNX) Are In A Position To Invest In Growth
Jan 01Companies Like Annexon (NASDAQ:ANNX) Are In A Position To Invest In Growth
Sep 08We Think Annexon (NASDAQ:ANNX) Can Afford To Drive Business Growth
May 22We Think Annexon (NASDAQ:ANNX) Can Afford To Drive Business Growth
Feb 06
Dosing underway in Annexon's Phase 2/3 study of monoclonal antibody in Guillain-Barré Syndrome
Dec 21Annexon Biosciences EPS misses by $0.43
Nov 16Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$115m |
| Mar 31 2024 | n/a | n/a | -US$121m |
| Dec 31 2023 | US$2m | US$593k | -US$134m |
| Sep 30 2023 | n/a | n/a | -US$141m |
| Jun 30 2023 | n/a | n/a | -US$143m |
| Mar 31 2023 | n/a | n/a | -US$145m |
| Dec 31 2022 | US$4m | US$569k | -US$142m |
| Sep 30 2022 | n/a | n/a | -US$145m |
| Jun 30 2022 | n/a | n/a | -US$145m |
| Mar 31 2022 | n/a | n/a | -US$140m |
| Dec 31 2021 | US$8m | US$534k | -US$130m |
| Sep 30 2021 | n/a | n/a | -US$116m |
| Jun 30 2021 | n/a | n/a | -US$103m |
| Mar 31 2021 | n/a | n/a | -US$84m |
| Dec 31 2020 | US$5m | US$446k | -US$70m |
| Sep 30 2020 | n/a | n/a | -US$56m |
| Jun 30 2020 | n/a | n/a | -US$45m |
| Mar 31 2020 | n/a | n/a | -US$42m |
| Dec 31 2019 | US$3m | US$396k | -US$38m |
| Sep 30 2019 | n/a | n/a | -US$34m |
| Jun 30 2019 | n/a | n/a | -US$28m |
| Mar 31 2019 | n/a | n/a | -US$23m |
| Dec 31 2018 | US$518k | US$379k | -US$18m |
Compensatie versus markt: De totale vergoeding ($USD 2.45M ) Doug } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 3.23M ).
Compensatie versus inkomsten: De vergoeding van Doug is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Doug Love (56 yo)
9.9yrs
Tenure
US$2,453,184
Compensatie
Mr. Douglas Love, Esq., J.D, also known as Doug, has been the President, Director and Chief Executive Officer of Annexon Inc. since December 2014. He has extensive business and legal leadership experience...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO, President & Director | 9.9yrs | US$2.45m | 0.28% $ 2.2m | |
| Chief Scientific Officer & Executive VP | 1.8yrs | US$1.83m | 0.048% $ 366.4k | |
| Executive VP | 3.1yrs | US$1.14m | 0.068% $ 519.6k | |
| Executive VP | 5.4yrs | US$1.44m | 0.026% $ 200.4k | |
| Executive VP & Chief Business Officer | 4.3yrs | US$1.40m | 0.034% $ 259.7k | |
| Senior Vice President of Translational Medicine | no data | geen gegevens | geen gegevens | |
| Executive VP & Chief Medical Officer | 1.3yrs | geen gegevens | geen gegevens | |
| Senior VP & Head of Commercial | less than a year | geen gegevens | geen gegevens | |
| Senior VP of Medical Affairs | less than a year | geen gegevens | geen gegevens |
2.5yrs
Gemiddelde duur
59.5yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van ANNX wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.5 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO, President & Director | 9.9yrs | US$2.45m | 0.28% $ 2.2m | |
| Executive VP | less than a year | US$1.14m | 0.068% $ 519.6k | |
| Independent Director | 9.9yrs | US$103.93k | 0.76% $ 5.9m | |
| Independent Chairman | 7.8yrs | US$132.43k | 0.00026% $ 2.0k | |
| Independent Director | 4.4yrs | US$100.93k | 0% $ 0 | |
| Independent Director | 3.3yrs | US$103.43k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens |
6.1yrs
Gemiddelde duur
66yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van ANNX wordt beschouwd als ervaren (gemiddelde ambtstermijn 6.1 jaar).